{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T02:52:21Z","timestamp":1793242341323,"version":"4.5.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100013126","name":"Psoriasis Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013126","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.jaad.2020.12.056","type":"journal-article","created":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T17:05:16Z","timestamp":1610125516000},"page":"110-120","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Biologic treatment outcomes in mucous membrane pemphigoid: A systematic review"],"prefix":"10.1016","volume":"87","author":[{"given":"Yuliya","family":"Lytvyn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahmina","family":"Rahat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asfandyar","family":"Mufti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Witol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Bagit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muskaan","family":"Sachdeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jensen","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2020.12.056_bib1","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1001\/archderm.138.3.370","article-title":"The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators","volume":"138","author":"Chan","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2020.12.056_bib2","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1067\/mjd.2000.107248","article-title":"Cicatricial pemphigoid","volume":"43","author":"Fleming","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.12.056_bib3","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.tripleo.2006.11.030","article-title":"Cicatricial pemphigoid with severe gingival and laryngeal involvement in an 18-year-old female","volume":"104","author":"Ojha","year":"2007","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"10.1016\/j.jaad.2020.12.056_bib4","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2017-220887","article-title":"Paraneoplastic mucous membrane pemphigoid with ocular and laryngeal involvement","volume":"2017","author":"Lambiel","year":"2017","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.jaad.2020.12.056_bib5","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/S0161-6420(90)32402-8","article-title":"Immunopathology of cicatricial pemphigoid affecting the conjunctiva","volume":"97","author":"Rice","year":"1990","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jaad.2020.12.056_bib6","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1046\/j.1365-2133.2001.04543.x","article-title":"Cicatricial pemphigoid with\u00a0circulating autoantibodies to beta4 integrin, bullous pemphigoid 180 and bullous pemphigoid 230","volume":"145","author":"Leverkus","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2020.12.056_bib7","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/1523-1747.ep12876206","article-title":"Studies of cicatricial pemphigoid autoantibodies using direct immunoelectron microscopy and immunoblot analysis","volume":"94","author":"Bernard","year":"1990","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2020.12.056_bib8","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1001\/archderm.138.3.380","article-title":"Interventions for mucous membrane pemphigoid\/cicatricial pemphigoid and epidermolysis bullosa acquisita: a systematic literature review","volume":"138","author":"Kirtschig","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2020.12.056_bib9","first-page":"375","article-title":"Corticosteroids: a review with emphasis on complications of prolonged systemic therapy","volume":"62","author":"Truhan","year":"1989","journal-title":"Ann Allergy"},{"key":"10.1016\/j.jaad.2020.12.056_bib10","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.jaad.2020.12.056_bib11","author":"The Centre for Evidence-Based Medicine"},{"key":"10.1016\/j.jaad.2020.12.056_bib12","first-page":"674","article-title":"Immunomodulation by IVIg and the role of Fc-gamma receptors: classic mechanisms of action after all?","volume":"5","author":"Nagelkerke","year":"2014","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaad.2020.12.056_bib13","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/BF02918224","article-title":"Suppressive effect of intravenous immunoglobulins on the activity of interleukin-1","volume":"13","author":"Okitsu-Negishi","year":"1994","journal-title":"Immunol Res"},{"key":"10.1016\/j.jaad.2020.12.056_bib14","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1159\/000237689","article-title":"In\u00a0vitro inhibitory activity of tumor necrosis factor alpha and interleukin-2 of human immunoglobulin preparations","volume":"114","author":"Menezes","year":"1997","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaad.2020.12.056_bib15","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1002\/eji.1830250521","article-title":"Selective induction of interleukin-1 receptor antagonist and interleukin-8 in human monocytes by normal polyspecific IgG (intravenous immunoglobulin)","volume":"25","author":"Ruiz de Souza","year":"1995","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.jaad.2020.12.056_bib16","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1007\/BF00920238","article-title":"Intravenous immunoglobulin induces interferon-gamma and interleukin-6 in\u00a0vivo","volume":"13","author":"Ling","year":"1993","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jaad.2020.12.056_bib17","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/eye.2016.284","article-title":"The 2016 Bowman lecture. Conjunctival curses: scarring conjunctivitis 30 years on","volume":"31","author":"Dart","year":"2017","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.jaad.2020.12.056_bib18","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1016\/S0161-6420(99)90496-7","article-title":"Intravenous immunoglobulin therapy for ocular cicatricial pemphigoid: a preliminary study","volume":"106","author":"Foster","year":"1999","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jaad.2020.12.056_bib19","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1001\/archderm.137.9.1181","article-title":"Comparison between intravenous immunoglobulin and conventional immunosuppressive therapy regimens in patients with severe oral pemphigoid: effects on disease progression in patients nonresponsive to dapsone therapy","volume":"137","author":"Ahmed","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2020.12.056_bib20","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1067\/mjd.2001.116339","article-title":"Intravenous immunoglobulin therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional immunosuppressive treatment","volume":"45","author":"Ahmed","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.12.056_bib21","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1067\/mjd.2001.116337","article-title":"Intravenous immunoglobulin therapy for patients with bullous pemphigoid unresponsive to conventional immunosuppressive treatment","volume":"45","author":"Ahmed","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.12.056_bib22","first-page":"119","article-title":"Intravenous immunoglobulins in the therapy of autoimmune and systemic inflammatory disorders","volume":"74","author":"Mobini","year":"1995","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaad.2020.12.056_bib23","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1067\/mjd.2001.112325","article-title":"High-dose intravenous immunoglobulins: an approach to treat severe immune-mediated and autoimmune diseases of the skin","volume":"44","author":"Rutter","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.12.056_bib24","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3389\/fimmu.2018.00248","article-title":"Effectiveness and safety of rituximab in recalcitrant pemphigoid diseases","volume":"9","author":"Lamberts","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaad.2020.12.056_bib25","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jaad.2016.01.020","article-title":"Rituximab combined with conventional therapy versus conventional therapy alone for the treatment of mucous membrane pemphigoid (MMP)","volume":"74","author":"Maley","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.12.056_bib26","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jaad.2012.10.018","article-title":"Critical analysis of the use of rituximab in mucous membrane pemphigoid: a review of the literature","volume":"68","author":"Shetty","year":"2013","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.12.056_bib27","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1001\/jamadermatol.2015.59","article-title":"Persistence of autoreactive IgA-secreting B cells despite multiple immunosuppressive medications including rituximab","volume":"151","author":"He","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2020.12.056_bib28","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jcv.2013.01.016","article-title":"Reactivation of latent viruses in individuals receiving rituximab for new onset type 1 diabetes","volume":"57","author":"Kroll","year":"2013","journal-title":"J Clin Virol"},{"key":"10.1016\/j.jaad.2020.12.056_bib29","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1080\/10428190701411441","article-title":"Rituximab-related viral infections in lymphoma patients","volume":"48","author":"Aksoy","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jaad.2020.12.056_bib30","doi-asserted-by":"crossref","first-page":"96","DOI":"10.3109\/09273948.2014.999377","article-title":"Rituximab and acute retinal necrosis in a patient with scleromalacia and rheumatoid arthritis","volume":"24","author":"Schuler","year":"2016","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.jaad.2020.12.056_bib31","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1001\/archdermatol.2011.54","article-title":"Rituximab for patients with refractory mucous membrane pemphigoid","volume":"147","author":"Le Roux-Villet","year":"2011","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2020.12.056_bib32","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.preteyeres.2004.05.005","article-title":"Ocular cicatricial pemphigoid: pathogenesis, diagnosis and treatment","volume":"23","author":"Ahmed","year":"2004","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.jaad.2020.12.056_bib33","doi-asserted-by":"crossref","first-page":"7313","DOI":"10.1016\/S0021-9258(20)89445-9","article-title":"Tumor necrosis factor. New insights into the molecular mechanisms of its multiple actions","volume":"266","author":"Vilcek","year":"1991","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jaad.2020.12.056_bib34","first-page":"3522","article-title":"Serum levels of tumor necrosis factor-alpha and interleukin-6 in ocular cicatricial pemphigoid","volume":"34","author":"Lee","year":"1993","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jaad.2020.12.056_bib35","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1167\/iovs.03-1138","article-title":"Role of macrophage migration inhibitory factor in conjunctival pathology in ocular cicatricial pemphigoid","volume":"45","author":"Razzaque","year":"2004","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jaad.2020.12.056_bib36","first-page":"2977","article-title":"Role of enhanced expression of m-CSF in conjunctiva affected by cicatricial pemphigoid","volume":"43","author":"Razzaque","year":"2002","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962221000104?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962221000104?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T23:03:19Z","timestamp":1759273399000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962221000104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S0190962221000104"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2020.12.056","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biologic treatment outcomes in mucous membrane pemphigoid: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2020.12.056","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}